Efficacy and Safety Study of 4975 in Patients Undergoing Total Hip Replacement

PHASE2TerminatedINTERVENTIONAL
Enrollment

118

Participants

Timeline

Start Date

September 30, 2007

Primary Completion Date

November 30, 2008

Study Completion Date

December 31, 2008

Conditions
Arthroplasty
Interventions
DRUG

4975, highly purified capsaicin

One dose administered by direct instillation into the surgical site

DRUG

Placebo

One dose administered by direct instillation into the surgical site

Trial Locations (10)

15143

Sewickley Valley Hospial, Sewickley

32127

Coastal Medical Research, Inc., Port Orange

35235

Alabama Clinical Therapeutics, LLC, Birmingham

48073

William Beaumont Hospital, Royal Oak

48085

William Beaumont Hospital, Troy

79410

Covenant Medical Center, Lubbock

91007

Lotus Clinical Research, Inc., Arcadia

91206

Glendale Adventist Medical Center, Glendale

94115

University of California at San Francisco - Mt. Zion, San Francisco

94612

Webster Orthopaedic Medical Group, Oakland

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Anesiva, Inc.

INDUSTRY

NCT00683267 - Efficacy and Safety Study of 4975 in Patients Undergoing Total Hip Replacement | Biotech Hunter | Biotech Hunter